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Abstract: Human herpesvirus 8 (HHV-8) is associated with Kaposi’s sarcoma, body cavity-based lymphoma, and Cas-
tleman’s disease. Adenoviral (Ad) E1A proteins regulate the activity of cellular and viral promoters/enhancers and tran-
scription factors and can suppress tumorigenicity of human cancers. As (i) HHV-8 and Ad may co-exist in immunocom-
promised patients and (ii) E1A might be considered as therapeutic transgene for HHV-8-associated neoplasms we investi-
gated whether the promoter of the latency-associated nuclear antigen (LANAp) controlling expression of vCyclin, vFLIP, 
and LANA proteins required for latent type infection is regulated by E1A. Transfection experiments in MV3 melanoma 
cells revealed activation of the LANAp by Ad5 E1A constructs containing an intact N terminus (aa 1-119). In particular, 
an Ad12 E1A mutant, Spm2, lacking six consecutive alanine residues in the “spacer” region activated the HHV-8 pro-
moter about 15-fold compared to vector controls. In summary, we report the activation of the LANAp by E1A as a novel 
interaction of E1A with a viral promoter. These data may have relevance for the management of viral infections in  
immunocompromised patients. A role for E1A as a therapeutic in this context remains to be defined. 
INTRODUCTION 
  Human herpesvirus 8 (HHV-8) was discovered in Ka-
posi’s sarcoma (KS) biopsy samples [1-3], primary effusion 
lymphomas (PEL) [4], multicentric Castleman’s disease [5], 
and plasmablastic lymphomas [6] and has been linked to 
pathogenesis of these disorders. The HHV-8 genome con-
sists of a double-stranded DNA of approximately 165 kb in 
size. Between conserved gene blocks, divergent regions con-
tain unique viral proteins, some of which mimic cell cycle 
regulation and signal transduction proteins required for lytic 
replication and latency [7]. Highly variable proteins such as 
products of the K1 open-reading frame have been used for 
molecular epidemiology studies [8]. In KS, HHV8 persists 
latently in the majority of tumor cells with fewer than 5% of 
cells undergoing spontaneous lytic replication [9, 10]. Map-
ping of transcripts involved in latency pointed to responsible 
genes such as ORF73, ORF72 encoding vCyc, a functional 
viral cyclin, and ORFK13 encoding vFLIP, a protein [11, 12] 
likely to have anti-apoptotic activity and contribute to the 
tumor phenotype [13]. 
  LANA, the latent nuclear antigen of HHV-8 (ORF73), is 
a multifunctional protein interacting with several cellular 
proteins suggesting a role in regulation of gene expression, 
and it has transforming activity in conjunction with H-ras 
[14]. It tethers the viral episomal DNA to the host cell chro-
mosomal DNA [15] and is able to bind p53, thus preventing  
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apoptosis [16]. Recent studies of HHV-8 latent replication 
and maintenance have revealed that two nuclear localization 
signals are located in the C-terminal region and N-terminal 
region of LANA [17] whereas the C-terminal domain of 
LANA is required for dimerization and DNA binding [18]. 
This interaction is necessary and sufficient for virus latency 
[19]. Suppression of the promoter of the latent genes may 
interrupt the latent life cycle of the virus and drive infected 
cells into apoptosis. 
  The E1A gene of human adenoviruses (Ad) is expressed 
early after infection and encodes multifunctional proteins 
that activate and suppress the transcription of both viral and 
cellular genes [20-22]. Due to alternative splicing Ad5 E1A 
encodes five different mRNAs. The two largest differentially 
spliced transcripts of Ad5 E1A encode polypeptides of 289 
and 243 amino acids (aa) that account for most if not all of 
E1A’s biologic activities. Four conserved regions (CRs) CR1 
to CR4 are highly homologous between different Ad sero-
types, and the CR3 containing a transactivation domain re-
sembles most of the 289aa protein-specific aa sequence [23]. 
The 243aa protein encodes all the functions necessary for 
immortalization of primary rodent cells or, in cooperation 
with other viral or cellular oncogenes, their full malignant 
transformation [24-26]. E1A proteins do not bind DNA 
themselves but control cell proliferation and transformation 
by modulating gene expression through interaction with sev-
eral cellular proteins. These include p105RB or the transcrip-
tional coactivator p300 that is involved in the regulation of 
many promoters. These activities of EIA have been reviewed 
extensively [22, 27-36]. 62    The Open Virology Journal, 2008, Volume 2  Koehler-Hansner et al. 
  Despite their transforming potential in rodent cells E1A 
proteins have shown broad tumor suppressive activity in a 
variety of human tumor cells, including the suppression of 
metastatic potential and induction of susceptibility to cy-
tostatic drugs and ionizing radiation [37-39]. In conse-
quence, E1A has already found its way into clinical trials 
targeting HER2/neu-overexpressing ovarian and breast can-
cer as well as head and neck cancer [40-42]. Safety and fea-
sibility of E1A gene therapy was established and in head and 
neck cancer patients a modest tumor response was observed 
[41] warranting further evaluation of E1A as a therapeutic 
candidate drug. 
  Because E1A is known to regulate other viral promoters, 
both positively (e.g. CMV) [43] and negatively (e.g. the 
HIV-1 LTR) [44], we asked whether E1A was also interfer-
ing with transcription from the LANAp of HHV-8. Since 
HHV-8 has been reported to latently infect a variety of ad-
herent tumor cell lines of epithelial, endothelial, and mesen-
chymal origin [45], we used a reporter cell system through-
out this study. In efforts to further improve the safety of E1A 
for clinical use we had found that in principle it is possible to 
separate transforming and reversing functions in a melanoma 
model [46, 47] and thus included respective deletion mutants 
of E1A in the present study. Here we report on activation of 
the LANAp in E1A-transfected cells. This finding may - 
apart from it’s impact for a putative gene therapy with E1A - 
also be of interest in a more general way since infections 
with viruses are problematic in immunocompromised hosts, 
e.g. in settings of bone marrow or organ transplantation 
where co-infections with different viruses may occur [48]. 
MATERIALS AND METHODOLOGY 
Cells 
  MV3, a human melanoma cell line [49] and BC-3 cells, a 
human PEL-derived B-cell line coinfected with HHV-8 were 
cultured as described [50, 51]. 
Plasmids 
  Construction of the luciferase gene plasmids HHV-8 WT 
promoter, del -262 and del -67 was described previously 
[52]. A del-59 reporter gene plasmid was constructed on the 
basis of the del-67 construct as follows: The LP1/2 fragment 
upstream from nt +30 relative to the start site was synthe-
sized by PCR with an antisense primer (+9 to +30) 5´-CCG 
CTCGAGCTGCCTCCAAATGATACACA-3´ and sense 
primer 88 bp HHV-8 (5´-CGGGGTACCCCAATCAGAAA 
GTAGCTTGA-3´) with the reporter gene plasmid 96 bp 
HHV-8 (pGL3.1) as template [52]. A second reporter gene 
plasmid, del-59Sp-1, was constructed using the Quick-
Change Multi Site-Directed Mutagenesis Kit (Stratagene, 
Heidelberg). The Sp-1 binding site was deleted according to 
the instructions of the manufacturer using the two primers 
5´-GTCCCGGGCGCCGCGTAGTGGAAGTTATATCAAG 
CTACTTTCTGATTG-3´ (sense) and 5´-CAATCAGAAAG 
TAGCTTGATATAACTTCCACTACGCGGCGCCCGGGA 
C-3´ (antisense) with the reporter gene plasmid and the 88 bp 
HHV-8 as templates. The E1A mutants used in this study 
were described previously [46, 47, 51]. The Spm2 construct 
expressed the Spm2 E1A mutant fused to the herpes virus 
VP22 tegument protein to increase intercellular spread [53]. 
 
Transient Transfections 
  MV3 cells were transiently transfected with JetPEI 
(Qbiogene, Heidelberg, Germany) in 24-well plates. Trans-
fection mixes contained 1 g of a HHV-8 promoter lu-
ciferase reporter plasmid and 1 ng, 10 ng, or 50 ng of E1A 
expression plasmids. Cells were lysed and luciferase activity 
was measured. Transfections of BC-3 cells were performed 
by electroporation (Bio-Rad Gene Pulser II, Bio-Rad Labo-
ratories, Munich, Germany) at settings of 230 mV and 975 
F in 0.4 cm cuvettes (Bio-Rad), using 2.9 x 10
7 
cells/cuvette resuspended in 0.35 ml RPMI 1640 medium 
supplemented with 15 % FCS and 1 % glutamine. Luciferase 
reporter constructs were constructed with the promoter of the 
latent genes of HHV-8 and its deletion mutants being fused 
to the luciferase vector pGL3b (Promega, Mannheim, Ger-
many). The positive control plasmid pGL3c was obtained 
from Promega, the negative control plasmids pRc/RSV and 
pVP22/myc-His used in this study were purchased from In-
vitrogen. Transfection experiments were performed three 
times and in triplicate. Transfections/electroporations with 
the pGL3c plasmid expressing the luciferase gene from the 
SV40 promoter/enhancer or a human telomerase reverse 
transcriptase (hTERT) promoter were included to score for 
successful transduction of the cells (data not shown). 
Luciferase Assays 
  Harvested cells were washed once with 1 ml PBS and 
lysed in 200 l of 1 x Glo Lysis buffer (Promega) for the 
cells transfected with JetPEI. Luciferase activity was meas-
ured according to the manufacturer´s recommendations 
(Promega, Mannheim, Germany). Results are given as rela-
tive luciferase activity or fold induction compared to the 
negative control plasmids, i.e. pRc/RSV or pVP22/myc-His 
for the experiments with Spm2 E1A; mean values +/- SD are 
depicted. 
Statistical Analysis 
  For statistical analysis the student’s t-test was used 
throughout all investigations. 
RESULTS 
Basal Activity of the LANAp in MV3 Cells 
  To confirm that the LANAp operates in MV3 melanoma 
cells, we assessed its ability to drive expression of a reporter 
gene in transiently transfected MV3 cells. Promoter-reporter 
gene recombinants were used where LANAp stretches of 
various length (Fig. 1) were cloned upstream to the reporter 
gene cassette. 
  The fusion sites were located in the 5´ untranslated leader 
sequence of the LT1 / 2 transcripts corresponding to nt 127-
870 [52]. Results from three independent experiments per-
formed in triplicate are shown in Fig. (2). When transfected 
into MV3 cells, an 804 bp HHV-8 WT promoter construct 
containing several transcription factor binding sites stimu-
lated luciferase expression. Truncation of the WT LANAp 
from the 5´ end enhanced the basal promoter activity, and a 
construct containing only 67 bp was able to initiate reporter 
transcription comparable to the del-262 plasmid. Further 
deletion of the promoter caused a decline in basal activity 
(Fig. 2). The del-59 HHV-8 promoter even showed a lower  
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basal activity than the WT LANAp. In the HHV-8-positive 
B-cell line BC3 higher luciferase activity was observed un-
der the control of the WT and the -262 LANAp (Fig. 2). 
Taken together, these experiments confirmed transcriptional 
activity of the LANAp in MV3 melanoma cells that were 
used in further cotransfection experiments. 
E1A Transactivates the LANAp 
  In order to examine transformation-negative Ad2 or Ad5 
and Ad12 E1A constructs for use as tumor-suppressive trans-
genes in gene therapy of malignant disease we had cloned a 
series of plasmids encoding the WT 13S and 12S mRNAs and 
various truncated forms thereof (Fig. 3) [47, 51]. 
  We here examined whether transcription from the LANAp 
was modulated by Ad2 and Ad12 E1A constructs in MV3 
reporter cells (Fig. 4). We found a 5 to 13-fold activation of 
transcription from the WT LANAp induced by Ad2 E1A 
while the VP22 control plasmid showed no transactivation 
(Fig. 4). 
  Ad12 12S E1A caused a dose-dependent transactivation of the 
LANAp. In particular, we observed significant transactivation capac-
ity (up to 25-fold) after transfection of the Ad12 Spm2 E1A plasmid 
(Fig. 5). The E1A-derivative Spm2 used in these experiments was 
fused to the VP22 HSV tegument protein [51] which mediates inter-
cellular transport of the fusion protein [53] and may thus allow a 
more efficient delivery of the transgene product. Furthermore, E1A-
 
Fig. (1). Schematic representation of the LANAp (not drawn to scale) and deletion mutants used in our studies. Transcription factor binding 
sites are also indicated. 
 
Fig. (2). Basal activity of the LANAp and its deletion mutants in MV3 cells (black bars) and BC-3 cells (white bars). Luciferase expression 
was measured after transfection of the cells with the indicated luciferase reporter constructs. MV3 cells were electroporated with 1 g of 
reporter gene plasmid; BC-3 cells were electroporated with 10 g of reporter gene plasmid. Relative luciferase activity is depicted. Data 
represent three independent experiments with transfection efficiency being 55 ± 15 (MV3) and 60 ± 10 (BC-3) %, respectively. 
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Spm2 was able to enhance the transactivation from the WT LANAp 
as well as from its deletion mutants -262, -67, -59, and even -59SP1. 
The latter construct lacks one of the most proximal SP1 sites (Fig. 5) 
and was silent in the MV3 cells (Fig. 2). 
 
Activation of Transcription from the LANAp by E1A 
Requires Aminoterminal E1A Sequences 
  To further investigate functional domains of the E1A 
proteins involved in transactivation of the LANAp, we stud-
ied whether deletion mutants of E1A were still able to acti-
 
Fig. (3). Diagram of the wild type and mutant Ad12 and Ad2/5 E1A-expressing plasmids used in this study. For details and references see 
materials and methods. NLS: Nuclear localization sequence.; CR1/2/3: Conserved region 1, 2, or 3. 
 
Fig. (4). LANAp is transactivated by the Spm2 and other E1A-encoding plasmids. MV3 cells were transfected with the WT LANAp con-
struct using 1 g of the pGL3-LANAp plasmid and the indicated amounts of the respective E1A constructs. Cells were harvested 48 h later 
and luciferase expression was measured. C = VP22 control plasmid. Relative luciferase activity is depicted. Data represent three independent 
experiments. The transfection efficiency was 50 ± 10%. *p< 0.005; §p < 0.001; #p<0.05. 
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vate this promoter. We found a 18 to 35-fold activation of 
transcription from the LANAp in the MV3 melanoma cell 
line by those Ad5 E1A constructs that contained an intact 
aminoterminus (13S and delCR2, Fig. (6); transfection effi-
ciency: 50 ± 15% each). The Ad5 E1A-CR3Ex2, Ad12 E1A-
Spex and Ad5 E1A-Ex2 constructs had essentially no effect. 
DISCUSSION 
  In this study we report evidence that the LANAp of 
HHV-8 can be up-regulated by Ad2 or Ad5 and Ad12 E1A 
gene products in MV3 human melanoma reporter cells. The 
MV3 reporter cell line was chosen for this initial series of 
experiments because it was easy to transfect. Moreover, 
studies to define regulatory elements of the LANAp and 
other latency-associated HHV-8 genes have been previously 
performed by others in a variety of adherent, non B-
lymphoid cell types, including HeLa, HEK293, and SLK 
cells demonstrating the general usability of these systems 
[52, 54, 55]. As shown here, the WT LANAp had basal ac-
tivity in the MV3 cells, although to a lesser extent than in B 
lymphoid BC-3 cells. 
  We detected an increase in basal LANAp activity upon 
truncation with the highest activity being confined to the -
262 construct and the lowest confined to pos. -67. This is 
inconsistent with the data from others who described a low 
activity of LANAp deletion constructs in HeLa cells and 
only minor influences of LANAp truncation down to -67 in 
BJAB cells [52]. The discrepancy between our data and the 
findings of Sarid et al. may be due to different cell lines 
since we found a 14-fold lower basal activity of the WT 
promoter in HeLa cells in comparison with MV3 cells (data 
not shown). Deletion of one of the postulated two SP-1 sites 
on the del-59 construct reduced the activity of the LANAp 
by about 90% suggesting that the first SP1 binding site 
downstream of the TATA box at position -27 is essential for 
LANAp promoter activity. We further suggest that the AP-
2 binding site upstream of the TATA box in addition to the 
SP1 binding sites downstream of the TATA box is necessary 
for efficient basal activation. Taken together, these data es-
tablish positive regulatory elements in the regions down-
stream of pos -262 and between pos. -67 and -1 of the 
LANAp, respectively, at least for its regulation in MV3 cells. 
The LANAp region spanning pos. -263 to -804 harbors sin-
gle or multiple binding sites for at least Sp-1, GR, Ap-1, 
Irf1/2, Myc, and Jun [52]. The binding sites responsible for 
the suppression observed in multiple cell systems remain to 
be defined; however, sequence analysis software (www. gene-
regulation.com/cgi-bin/pub/programs/alibaba2/webbaba 2.cgi) 
identified a suppressor element at pos. -440 of the LANAp 
(Köhler, unpublished data). It should be noted that this nega-
tive regulation was not observed in BC-3 cells, consistent 
with findings of Jeong et al. in BJAB cells and BC-3 cells of 
lymphocytic origin [54]. Of note, Jeong et al. observed a 
substantial increase of luciferase activity driven by LANAp 
constructs in adherent cells like HEK293 when sequences 
from pos. -1490 to -279 were deleted [54]. In summary, we 
showed that a minimal region starting at position -67 from 
the transcription start site defined at nt 127-900 [52] or 127-
880 [55] is necessary and sufficient for constitutive promoter 
activity and also for robust expression from the LANAp in 
the MV3 cell line. 
  When low amounts of plasmids encoding the 13S and 
12S cDNAs of Ad2 and Ad12, respectively, were cotrans-
fected with the LANAp constructs, a dose-dependent activa-
tion of the WT LANAp was detected in MV3 cells. A more 
pronounced induction was found when the Ad12 Spm2 mu-
tant was used. It is of particular interest that Spm2 induced 
transcription from truncated LANAps down to the del-59 
construct and even from the del-59Sp-1 mutant. Thus, Spm2 
E1A seems to be able to override (i) the influence of the 
negative regulatory element between pos. -263 and -804 in 
MV3 cells and, moreover, (ii) the requirement for the Sp-1-
site that is deleted in the construct del-59Sp-1 for basal 
LANAp activity in these cells. Spm2, a transformation-
 
Fig. (5). Comparison of Ad12 Spm2 E1A-mediated dose-dependent activation of transcription in MV3 cells between the del 59 SP1, the del -
59, the del -67, the del -262 and the complete 804 bp HHV-8 promoter constructs. The transfection procedure was as described in Fig. (4). 
Mean relative promoter activities compared to controls and standard deviations obtained from nine transfections in triplicate are shown. The 
transfection efficiency was 50 ± 10%. 
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defective derivative of Ad12 E1A lacking six consecutive 
alanines in the Ad12-specific so-called “spacer” region im-
pairing binding to Rb [46] is able to stimulate transcription 
from the human TERT promoter in melanoma cells without 
activating TERT in non-transformed fibroblasts [51]. 
Moreover, there is some evidence that Spm2 may harbor 
tumor-suppressive activity in vivo (Kirch et al., unpublished 
observations). However, the Spm2 construct contained the 
VP22 domain considered to enhance cell-to-cell spread of 
fusion proteins [56], thereby possibly increasing the protein 
dosage per cell as well as the number of cells transduced. As 
E1A has recently been reported to have dramatically differ-
ent effects depending on expression levels in the 3T3L1 
preadipocytic cell line [57], such gene dosage effects have to 
be seriously considered and await further investigation. We 
and others have previously ruled out a direct transactivating 
effect of VP22 sequences [47, 51, 56]. 
  N-terminal sequences of E1A, i.e. aa positions 1-119, 
proved to be a necessary prerequisite for activation of the 
LANAp. This region of E1A contains transcriptional activa-
tion properties in which binding sites for a multitude of tran-
scriptional activators and enhancers are located, in particular 
AP-2- and CBP/p300-binding sites [27]. 
  In contrast to others [54, 55] we did not detect any 
autoactivation of the LANAp by cotransfection of plasmids 
encoding LANA itself or a combination of vFLIP, vCyclin, 
and LANA (data not shown). Moreover, cotransfection of 
these plasmids did not interfere with stimulation of transcrip-
tion from the LANAp by Spm2 E1A. Mechanisms for these 
observations remain to be elucidated. 
  In a preliminary series of experiments neither cotransfec-
tion of Ad2 E1A nor Ad12 E1A Spm2 with the WT LANAp 
in HHV-8-positive BC-3 cells resulted in any substantial 
activation of the LANAp (data not shown). Whether these 
observations reflect a biological phenomenon or rather tech-
nical problems remains unclear; in the BC-3 cells we also 
observed only a marginal activation of a Hsp70 positive con-
trol promoter that was highly active in the MV3 cells (data 
not shown). The RSV promoter controlling E1A expression 
in most of our constructs has been reported to be active in B-
lymphoid cells [58]. Pilot experiments using a GFP expres-
sion plasmid revealed a transfer efficiency of 55±15 % when 
the optimized electroporation protocol was used and 40 ± 
12.5% as scored by fluorescence microscopy when cotrans-
fections were performed (data not shown). Further experi-
mental efforts will be required to test whether our findings 
reported here hold also true for the context of a B cell envi-
ronment. 
  Recently, novel regulatory elements and mechanisms 
controlling protein expression at the RNA level have been 
described. These are miRNAs that can induce specific silenc-
ing of mRNAs and the RNA editing, the post-transcriptional 
sequence modification of primary transcripts. MiRNAs are 
also encoded by viruses and can be orthologous to cellular 
counterparts [59]. A cluster encoding HHV-8-specific miR-
NAs has been found within a region transcribed under the 
control of the LANAp as well as other promoters [60]. RNA 
editing [61] has been shown to control the biological func-
tions of the HHV-8 Kaposin protein [62]. These results - 
only very briefly mentioned here – call for the need to fur-
ther elucidate the more complex regulation of protein ex-
pression by tumor-inducing viruses like HHV-8. 
 
Fig. (6). The HHV-8 promoter is transactivated by Ad5 E1A and the E1A deletion mutant delCR2. E1A derivatives lacking an intact 
aminoterminus were not able to transactivate the LANAp. The transfection procedure was as described in Fig. (4). Data represent three inde-
pendent experiments with transfection efficiency being 50 ± 15%. *p< 0.005. 
 
0
5
10
15
20
25
30
35
40
45
50
51 051 051 051 051 0C
-
f
o
l
d
13 S delCR2 CR3EX2 Ex2 Spex
Ad5 Ad12
+ WT LANAp
*
* *
*
R
e
l
a
t
i
v
e
 
I
n
c
r
e
a
s
e
i
n
 
L
u
c
i
f
e
r
a
s
e
A
c
t
i
v
i
t
y
E1A-encoding
plasmidsInteraction of Adenovirus E1A with the HHV8 Promoter of Latent Genes  The Open Virology Journal, 2008, Volume 2    67 
CONCLUSIONS 
  Taken together, we show, to our knowledge for the first 
time, that E1A can regulate and activate the LANAp of 
HHV-8, at least in MV-3 reporter cells. Thus, our data add 
the LANAp to the many cellular and viral promoters modu-
lated by E1A. Whether this holds true for naturally HHV-8-
containing cells remains to be determined since technical 
problems with our experiments failing to prove this in BC-3 
cells cannot be ruled out at present. Whether this activity of 
E1A has implications for its use as a gene therapeutic re-
mains elusive. The observation that downregulation of 
LANA by the small molecular weight component glycyr-
rhizic acid can induce apoptosis [63] would favor a down-
regulation by E1A, too. In this respect our data would cau-
tion the therapeutic application of E1A in HHV-8-positive 
tumor patients. However, it is not yet known whether a 
maintenance of HHV-8 latency by E1A-mediated upregu-
lated LANA rather than conversion to the lytic cycle might 
be beneficial, maybe in combination with cytotoxic or anti-
viral drugs. For severely immunocompromised patients, e.g. 
after organ transplantation, possibly infected among other 
viruses by HHV-8 and Ad concomitantly it may be of avail 
to know that Ad’s gene products can interact with HHV-8 
regulatory elements, presumably in an undesired fashion. 
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